Company Encyclopedia
View More
name
CH BIOTECH SER
08037.HK
China Biotech Services Holdings Limited, an investment holding company, provides medical laboratory testing and health check services in the People’s Republic of China and Hong Kong. The company operates through Medical and Health Related Services, Immunotherapy, Pharmaceutical Products, Insurance Brokerage, BNCT, and Others segments. It also engages in the provision of tumor immune cell therapy and health management services; sale and distribution of health related and pharmaceutical products; insurance brokerage services; provision of boron neutron capture therapy treatment services; provision of logistic services; and property investment activities. The company was formerly known as Rui Kang Pharmaceutical Group Investments Limited and changed its name to China Biotech Services Holdings Limited in November 2017.
50.03 B
08037.HKMarket value -Rank by Market Cap -/-

Financial Score

22/12/2025 Update
D
Health Care ServicesIndustry
Industry Ranking21/28
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-47.76%E
    • Profit Margin-195.28%E
    • Gross Margin6.54%E
  • Growth ScoreB
    • Revenue YoY23.93%A
    • Net Profit YoY-3.70%C
    • Total Assets YoY-14.61%E
    • Net Assets YoY-44.43%E
  • Cash ScoreC
    • Cash Flow Margin-51.21%D
    • OCF YoY23.93%A
  • Operating ScoreE
    • Turnover0.13E
  • Debt ScoreD
    • Gearing Ratio60.65%D

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    CH BIOTECH SER's subsidiary has been granted a loan with a principal amount of up to 180 million yuan

    CH BIOTECH SER announced that its wholly-owned subsidiary Pengbo (Hainan) has signed a loan agreement with Hainan Rural Commercial Bank, with a maximum loan amount of 180 million yuan. The loan will be used to construct a boron neutron capture therapy center, expected to open by the end of 2025, providing treatment services for cancer patients. The company plans to develop a network of treatment centers covering China with the support of the Boao Lecheng Pilot Zone, creating more revenue

    Zhitong·
    HK
    08037
    -7.61%
    Zhitong·
    HK
    08037
    -7.61%

    CH BIOTECH SER announced its interim results, with a loss attributable to shareholders of HKD 32.06 million, a year-on-year narrowing of 59.95%

    CH BIOTECH SER announced its mid-term results for 2025, with revenue of HKD 38.872 million, a year-on-year increase of 19.79%; the loss attributable to shareholders was HKD 32.006 million, a year-on-year narrowing of 59.95%; the loss per share was HKD 0.033. The improvement in loss was mainly due to the successful implementation of cost control measures, an increase in gross profit margin, a reduction in administrative expenses, and the receipt of approximately HKD 13.7 million in insurance compensation income

    Zhitong·
    HK
    08037
    -7.61%
    Zhitong·
    HK
    08037
    -7.61%

    CH BIOTECH SER expects a mid-term loss attributable to shareholders to decrease by approximately 59% year-on-year

    CH BIOTECH SER expects that the loss attributable to shareholders in the middle of 2025 will not exceed HKD 33 million, a year-on-year decrease of approximately 59%. The main reasons include successful implementation of cost control measures, an increase in gross profit margin, a reduction in administrative expenses, and the receipt of approximately HKD 14 million in insurance compensation income

    Zhitong·
    HK
    08037
    -7.61%
    Zhitong·
    HK
    08037
    -7.61%

    AXA and the Hainan Boao Lecheng Administration signed a cooperation agreement to explore innovative medical insurance models

    AXA and the Hainan Boao Lecheng International Medical Tourism Pilot Zone Administration signed a cooperation agreement aimed at exploring innovative medical insurance models, utilizing Lecheng's medical resources to provide customers with cross-border medical options. Hainan Boao Lecheng is the only medical special zone in the country, enjoying multiple preferential policies. AXA is also exploring the boron neutron capture therapy technology project in collaboration with CH BIOTECH SER. The Chief Life and Medical Insurance Business Director of AXA Hong Kong and Macau stated that this cooperation will help provide diversified treatment options

    AASTOCKS·
    HK
    08037
    -7.61%
    AASTOCKS·
    HK
    08037
    -7.61%

    CH BIOTECH SER appoints Yin Ye as Executive Director

    CH BIOTECH SER announced that Dr. Yin Ye has been appointed as Executive Director, and Dr. Zhang Xiao as Independent Non-Executive Director and member of the Audit Committee, effective from July 25, 2025. At the same time, Qian Hongji resigned as Independent Non-Executive Director and member of the Audit Committee due to other business commitments, Lin Deming resigned as Company Secretary and Authorized Representative, and Chief Financial Officer Feng Peixian was appointed as Company Secretary and Authorized Representative

    Zhitong·
    HK
    08037
    -7.61%
    Zhitong·
    HK
    08037
    -7.61%
    © 2025 Longbridge｜Disclaimer